Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review

Digestion

Volumn 62, Issue SUPPL. 1, 2000, Pages 84-91

  Arnold, Rudolf ^a   Simon, B ^a   Wied, M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

GEP tumours; Long acting somatostatin analogues; Medical treatment; Neuroendocrine tumours; Octreotide

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; OCTREOTIDE; PROTON PUMP INHIBITOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

CANCER INHIBITION; CARCINOID SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; DRUG HALF LIFE; DRUG MECHANISM; GALLSTONE; GLUCAGONOMA; HUMAN; INSULINOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; STOMACH ACID SECRETION; SUSTAINED RELEASE PREPARATION; SYMPTOMATOLOGY; TUMOR GROWTH; VERNER MORRISON SYNDROME; ZOLLINGER ELLISON SYNDROME;

EID: 0033839620     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051861     Document Type: Conference Paper

References (53)

1. Reisine T, Bell GI: Molecular biology of somatostatin receptors. Endocr Rev 1995;6:427-442.
2. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino J, Seino Y: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-1325.
3. Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994;135:2814-2817.
4. Chen L, Fitzpatrick VD, Vandlen RL, Tashjian AH: Both overlapping and distant signaling pathways for somatostatin receptor SSTR1 and SSTR2 in pituitary cells. J Biol Chem 1997; 272:1866-1872.
5. Buscail L, Esteve JP, Saint Laurent N, Bertrand V, Reisine T, O'Carrol AM, et al: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995;92:1580-1584.
6. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charbonneau JW, Reading CC, Moertel C: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-5977.
7. Wulbrand U, Wied M, Zofel P, Göke B, Arnold R, Fehmann CH: Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998; 28:1038-1049.
8. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M: Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumours. Clin Cancer Res 1999;5: 3483-3487.
9. ®: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995;44:18-26.
10. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996;38: 430-438.
11. Ch'ng JL, Anderson JV, Williams SJ, Carr DH, Bloom SR: Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumours with long-acting somatostatin analogue. Br Med J 1986;292:981-982.
12. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin L, Hahn RG: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-666.
13. Ruszniewski P, Duereux M, Chayvialle JA, et al: Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 1996;39:279-283.
14. Scherübl H, Wiedenmann B, Riecken EO, et al: Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 1994;10:1591-1592.
15. Vinik A, Moattari AR: Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989;34(suppl):149-275.
16. Wood SM, Kraenzlin MW, Adrian TE, Bloom SM: Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: Symptomatic and peptide responses. Gut 1985;25:438-444.
17. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-606.
18. Ruskoné A, Rene E, Chayvialle JA, Bonin N, Pignal F, Kremer M, Bonfils S, Rambaud JC: Effect of somatostatin on diarrhea and on small intestine water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 1982;27:459-466.
19. Maton PN, O'Dorisio TM, Howe BA, et al: Effect of long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1985;312:17-21.
20. O'Dorisio TM, Mekhjan H, Gaginella TS: Medical therapy of VIPomas. Endocrinol Clin North Am 1989;18:545.
21. Santangelo WC, O'Dorisio Th, Kim JG, et al: Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med 1985;103: 363-367.
22. Guillausseau PJ, Guillausseau-Scholer C: Glucagonomas: Clinical presentation, diagnosis, and advances in management; in Mignon M, Jensen RT (eds): EndocrineTumors of the Pancreas. Front Gastrointest Res. Basel, Karger, 1995. vol 23, pp 183-193.
23. Creutzfeldt W, Arnold R, Creutzfeldt C, Track NS: Pathomorphologic, biochemical and diagnostic aspects of gastrinoma (Zollinger-Ellison syndrome). Hum Pathol 1975;6:47-76.
24. Ruszniewiski P, Laucournet H, Elounar-Blanc L, Mignon M, Bonfils S: Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: Evidence for sustained efficacy. Pancreas 1988;3:145-152.
25. Vinik AL, Shih-tzer T, Moattari AR, Chcung P: Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery 1988;104: 834-842.
26. Koop H, Klein M, Arnold R: Acid inhibitory effects of somatostatin analog in malignant gastrinoma. J Clin Gastroenterol 1990;12:120-121.
27. Metz DT, Jensen RT: Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome; in Mignon M, Jensen RT (eds): Endocrine Tumours of the Pancreas. Recent Advances in Research and Management. Front Gastrointest Res. Basel, Karger, 1995, vol 21 pp 240-257.
28. Maton PN, Gardner JD, Jensen RT: Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet cell tumours. Dig Dis Sci 1989;34(suppl):285-291.
29. Nauck M, Stöckmann F, Creutzfeldt W: Evaluation of a euglycaemic clamp procedure as a diagnostic test in insulinoma patients. Eur J Clin Invest 1990;20:15-18.
30. Dowling RH, Hussaini SH, Murphy GM, et al: Gallstones during octreotide therapy. Metabolism 1992;41(suppl 2):22-23.
31. Halma C, Jansen JB, Janssens R, et al: Life-threatening water intoxication during somatostatin therapy. Ann Intern Med 1987;107:518-529.
32. Taylor JE, Bogden AE, Moreau JP, Coy DH: In vitro inhibition of human small cell lung carcinoma (NCL-H69) growth by somatostatin analogue. Biochem Biophys Res Commun 1988; 153:81-86.
33. Siegel RA, Tolseavai L, Rudin M: Partial inhibition of the growth of transplanted Dunning rat prostate tumors with the long-acting somatostatin analogue Sandostatin (SMS 201-995). Cancer Res 1988;153:4651-4655.
34. Liebow C, Reilly C, Serrano M, Schally AV: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989;86:2001-2007.
35. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella O, Kalthoff H, Vaysse N, Susini C: Loss of sst2 somatostatin receptor gene expression in human pancreatic and colo rectal cancer. Cancer Res 1996;56:1823-1827.
36. Sharma K, Patel YC, Srikant CB: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10:1688-1696.
37. Florio T, Scorziello A, Fattore M, D'Alto V, Salzano S, Rossi G, et al: Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphothyrosine phosphatase activity. J Biol Chem 1996;271:6129-6136.
38. Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carrol AM, Schally AV, et al: Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sstr5. Proc Natl Acad Sci USA 1997;921:580-584.
39. Shepherd JJ, Senator GB: Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet 1986; ii:574.
40. Wiedenmann B, Räth U, Rädsch R, Becker F, Kommerell B: Tumour regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995. Klin Wochenschr 1988;66:75-77.
41. Saltz L, Trochanowsky G, Buckley M, Heffernan B, Niedzwicki D, Tao Y, Kelsen D: Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993;72:244-248.
42. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, Di Leo A and the ITMO Association: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 1996;77: 402-408.
43. Eriksson B, Renstrup J, Iman H, Öberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 1997;8:1041-1044.
44. Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B: Ultra-high dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumours. Digestion 1999;60:469-476.
45. Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R: Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: Report of one case and review of the literature. Digestion 1989;42:116-120.
46. Sharma K, Srikant CB: Induction of wild-type p53, BAX, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998;76: 259-266.
47. Kraenzlin ME, Ch'ng JC, Wood SM, Bloom SR: Can inhibition of hormone secretion be associated with endocrine tumour shrinkage. Lancet 1983;ii:1501-1504.
48. Clements D, Elias E: Regression of metastatic VIPoma with somatostatin analogue SMS 201-995. Lancet 1985;1:874-875.
49. Arnold R, Neuhaus C, Benning R, et al: Somatostatin analog Sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 1993;17:511-519.
50. Gordon PH: NIH Conference: Somatostatin and somatostatin analogue (SMS 201-995) in the treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern 1989; 110:35-50.
51. Joensun H, Kätkä K, Kujari H: Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenh) 1992;126:184-185.
52. Janson ET, Öberg K: Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-229.
53. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R: Combination therapy with octreotide and α-interferon: Effect of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1382-1387.